Uncategorized Archives - Page 35 of 145

TuesdayJun 06, 2023 3:07 pm

New Computational Platform to Broaden Options of Potential Immunotherapy Targets in Cancer Treatment

Immunotherapy is a relatively novel way of treating cancer. It entails boosting one’s immune system so it can locate and destroy cancer cells. This type of treatment is typically recommended for patients suffering from cases of advanced cancer, and it can be used to address conditions such as kidney cancer, lymphoma, bladder cancer and non-small cell lung cancer. Since immunotherapy has only been around since the 1980s, researchers and clinicians are constantly working to make the treatment safer and more effective for cancer patients. A team of researchers from UCLA and the Children’s Hospital of Philadelphia (CHOP) have now created…

FridayJun 02, 2023 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Displays CDMO Expertise at Prestigious Biomed Israel Conference

Biotechnology innovator BiondVax Pharmaceuticals is dedicated to developing nanosized antibody (NanoAb) treatment BiondVax is also leveraging its team experience in preclinical stage to Phase 3 clinical trial product development to generate new revenues by offering cGMP contract development and manufacturing organization (“CDMO”) services The company recently exhibited its CDMO expertise as well as its NanoAb development pipeline at the 21st annual Biomed Israel conference, which drew over 6,000 attendees from a wide variety of international life sciences disciplines BiondVax’s NanoAb drug candidate pipeline has expanded focus on immune system cytokine targets for treating psoriasis and psoriatic arthritis Israel-based biotechnology company…

FridayJun 02, 2023 9:15 am

Genprex Inc.’s (NASDAQ: GNPX) Inspiring Patient Video on Gene Therapy’s Potential in NSCLC Treatment

Gene Therapy's Transformative Potential Highlighted in Inspiring Patient Video Interview with Genprex’s (NASDAQ: GNPX) REQORSA on Benzinga. Click Here for the full article The interview showcases the real-life experience of a patient participating in a clinical trial utilizing Genprex's innovative gene therapy drug candidate, REQORSA, shedding light on the significant impact it could potentially have in advancing the treatment of non-small cell lung cancer. The featured video highlights the compelling story of Jacqueline Marino, a participant in the Phase 1 segment of Genprex's Phase 1/2 Acclaim-1 clinical trial. Marino, diagnosed with non-small cell lung cancer (“NSCLC”), offers an inspiring account…

TuesdayMay 30, 2023 12:00 pm

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives Buy Rating and $70 Target Price; Releases Q1 2023 and Business Update

Analysts at Aegis Capital Corp. continue to recommend shares of the company with a Buy rating and a $70 target price Data from pre-clinical trial indicate that BiondVax’s NanoAb may effectively serve as both a therapeutic and protective prophylactic drug, further enhancing its value proposition BVXV reiterated further NanoAb development beginning with NanoAbs targeting immune system cytokines such as IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis BiondVax aims to optimize the use of assets and generate additional revenues by offering its drug development services and cGMP manufacturing capabilities to others BiondVax Pharmaceuticals (NASDAQ: BVXV),…

FridayMay 26, 2023 9:00 am

NextPlat Corp. (NASDAQ: NXPL) Celebrates Great Day in Miami with More on the Way

NextPlat inks deal to provide American businesses easy access to Chinese consumer market E-Commerce Development Program in collaboration with Tmall Global announced at Miami event Tmall Global e-commerce platform will provide NextPlat customers simple turnkey solution to sell products to the Chinese consumer market First in a series of new e-commerce development programs designed to provide US businesses swift, easy e-commerce access to new international customers April 24, 2023, was a great day in Miami for NextPlat (NASDAQ: NXPL, NXPLW) and U.S. businesses eager to expand their e-commerce efforts and market goods to the multitrillion-dollar Chinese consumer market. In collaboration…

ThursdayMay 25, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Provides Business Update, Reports FY2022 Financial Results

Biotechnology innovator BiondVax Pharmaceuticals recently provided a business update and published full-year financial results for the period ended December 31, 2022 Achievements realized to date leave CEO Amir Reichman optimistic about the company’s growth potential and ability to deliver value to shareholders The company enjoys definitive, exclusive agreements including options for exclusive worldwide licenses with the Max Planck Society and the University Medical Center Göttingen, Germany to enable it to build a pipeline of ‘biobetter’ nanosized VHH antibodies (“NanoAbs”) Pipeline to target diseases with attractive commercial opportunities such as psoriasis, psoriatic arthritis, COVID-19, macular degeneration and asthma Biotechnology innovator BiondVax…

WednesdayMay 24, 2023 10:30 am

NextPlat Corp. (NASDAQ: NXPL) Inks Deal to Open Doors for US Business to ‘Mammoth’ Chinese Consumer Market

NextPlat, Tmall Global sign merchant sourcing agreement designed to give U.S. businesses easy access to Chinese e-commerce market. Tmall Global e-commerce platform will provide NextPlat customers a turnkey solution to sell products to the Chinese consumer market. Starting in Florida, NextPlat intends to expand E-Commerce Development Program businesses throughout the United States and all of the Americas. Turnkey international e-commerce solution simplifies the process, provides American-based companies opportunity of new business in China. In a collaboration designed to be the “first in a series of new e-commerce development programs,” global e-commerce provider NextPlat (NASDAQ: NXPL) and Alibaba Group Holding Limited…

WednesdayMay 17, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting

Positive preclinical data was presented for the NPRL2 tumor suppressor gene The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models Validates ONCOPREX(R) platform’s ability to deliver other tumor suppressor genes to potentially address multiple types of cancer ONCOPREX(R) Nanoparticle Delivery System is the novel non-viral platform being used for the company’s lead drug candidate, REQORSA(R) Immunogene Therapy, initially targeting lung cancer Genprex (NASDAQ: GNPX), A cutting-edge gene therapy company striving to improve the lives of cancer and diabetes patients through the creation of groundbreaking treatments,…

WednesdayMay 10, 2023 9:00 am

NextPlat Corp. (NASDAQ: NXPL) Is ‘One to Watch’

NextPlat is led by a highly experienced management team, board of directors and advisors with proven expertise in M&A, finance, e-commerce, media, technology and health care The company operates a state-of-the-art e-commerce platform serving customers in over 195 countries NextPlat recently announced a new e-commerce development program in collaboration with Alibaba’s Tmall Global to provide American businesses easy access to the Chinese consumer market, with plans to expand throughout the Americas Positioned as the e-commerce platform of the future, NextPlat’s system is now being upgraded with Web3 capabilities to seamlessly enable the sale of both tangible and digital assets Its…

TuesdayApr 25, 2023 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aims to Complement its NanoAb Core Focus with Comprehensive Contract Development and Manufacturing Organization Services

BiondVax intends to expand its contract development and manufacturing organization (“CDMO”) offering as it continues the primary focus on its NanoAb pipeline development The CDMO services include aseptic fill and finish, upstream and downstream process development, as well as analytical model development and analytical testing This is made possible by BiondVax’s state-of-the-art assets in Jerusalem, Israel, including GMP-ready production clean rooms, fermentors, WFI, analytic tools, media, and buffer preparations With a combined 17 years of experience in recombinant protein process development from bench to Phase 3, BiondVax’s boutique CDMO service is well positioned to meet client needs BiondVax Pharmaceuticals (NASDAQ:…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

New Computational Platform to Broaden Options of Potential Immunotherapy Targets in Cancer Treatment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Displays CDMO Expertise at Prestigious Biomed Israel Conference

Genprex Inc.’s (NASDAQ: GNPX) Inspiring Patient Video on Gene Therapy’s Potential in NSCLC Treatment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives Buy Rating and $70 Target Price; Releases Q1 2023 and Business Update

NextPlat Corp. (NASDAQ: NXPL) Celebrates Great Day in Miami with More on the Way

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Provides Business Update, Reports FY2022 Financial Results

NextPlat Corp. (NASDAQ: NXPL) Inks Deal to Open Doors for US Business to ‘Mammoth’ Chinese Consumer Market

Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting

NextPlat Corp. (NASDAQ: NXPL) Is ‘One to Watch’

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aims to Complement its NanoAb Core Focus with Comprehensive Contract Development and Manufacturing Organization Services

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search